GlassScriptPhysician profile
Suchitra Sundaram
NPI 1083979983
$2,637.09
in general payments reported to CMS, 2019-2025
14 companies · $684 in 2025
The $684 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2021: $199 · 2022: $163 · 2023: $197 · 2024: $802 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,325 · Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,325.00 |
| Food and Beverage | $357.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Astrazeneca Pharmaceuticals LP | $592.40 | 2019 | |
| Eurofins Viracor, LLC | $187.91 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.15 | 2022 | |
| Pfizer INC. | $126.82 | 2024 | |
| Genentech USA, INC. | $99.79 | 2023 | |
| Eli Lilly and Company | $97.00 | 2023 | |
| Recordati_rare_diseases_inc. | $33.53 | 2025 | Sylvant |
| Morphosys, US INC. | $16.99 | 2022 | |
| Epizyme, INC. | $11.50 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suchitra Sundaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.